SG Americas Securities LLC Sells 52,542 Shares of InMode Ltd. (NASDAQ:INMD)

SG Americas Securities LLC decreased its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 82.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 10,825 shares of the healthcare company’s stock after selling 52,542 shares during the period. SG Americas Securities LLC’s holdings in InMode were worth $241,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Exchange Traded Concepts LLC increased its stake in shares of InMode by 1,910.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 18,070 shares of the healthcare company’s stock valued at $402,000 after purchasing an additional 17,171 shares in the last quarter. Vanguard Group Inc. increased its position in shares of InMode by 9.1% during the third quarter. Vanguard Group Inc. now owns 889,004 shares of the healthcare company’s stock valued at $27,079,000 after acquiring an additional 74,082 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in shares of InMode during the third quarter valued at approximately $47,000. Citigroup Inc. increased its position in shares of InMode by 1.6% during the third quarter. Citigroup Inc. now owns 63,332 shares of the healthcare company’s stock valued at $1,929,000 after acquiring an additional 975 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in shares of InMode during the third quarter valued at approximately $317,000. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

Shares of InMode stock opened at $18.47 on Friday. The company’s fifty day simple moving average is $21.85 and its 200-day simple moving average is $22.55. The stock has a market capitalization of $1.55 billion, a PE ratio of 8.03 and a beta of 2.16. InMode Ltd. has a 1-year low of $17.74 and a 1-year high of $48.25.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The business had revenue of $126.80 million for the quarter, compared to analysts’ expectations of $124.77 million. InMode had a net margin of 40.22% and a return on equity of 29.80%. The company’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.69 EPS. As a group, research analysts anticipate that InMode Ltd. will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Tuesday. UBS Group raised their target price on shares of InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, February 14th. Finally, Barclays raised their target price on shares of InMode from $32.00 to $34.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, InMode presently has a consensus rating of “Hold” and a consensus target price of $33.00.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.